Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind,Randomized,Parallel-Group,Vehicle-Controlled,MulticenterStudy ComparingaGenericTazaroteneCream,0.1%toReference Listed Drug Tazorac® Cream, 0.1% and Both Active Treatments to Vehicle Control in the Treatment of Acne Vulgaris

NCT02160678 is registered in ClinicalTrials.gov with G & W Laboratories Inc. as lead sponsor.

NCT NCT02160678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02160678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind,Randomized,Parallel-Group,Vehicle-Controlled,MulticenterStudy ComparingaGenericTazaroteneCream,0.1%toReference Listed Drug Tazorac® Cream, 0.1% and Both Active Treatments to Vehicle Control in the Treatment of Acne Vulgaris
Lead sponsor
G & W Laboratories Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2014
Completion date
July 31, 2015
Enrollment
1,741 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acne vulgaris